LeMaitre Vascular (LMAT) Expected to Release Earnings on Wednesday

LeMaitre Vascular (NASDAQ:LMAT) will likely be posting its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect LeMaitre Vascular to post earnings of $0.6860 per share and revenue of $67.39 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.07). The firm had revenue of $70.38 million for the quarter, compared to the consensus estimate of $71.47 million. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The company’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.60 EPS. On average, analysts expect LeMaitre Vascular to post $2.89 EPS for the current fiscal year and $3.18 EPS for the next fiscal year.

LeMaitre Vascular Stock Down 0.2%

Shares of NASDAQ LMAT opened at $81.13 on Tuesday. The company has a debt-to-equity ratio of 0.40, a current ratio of 16.31 and a quick ratio of 13.96. The company has a 50-day moving average price of $81.19 and a 200-day moving average price of $94.18. The stock has a market capitalization of $1.86 billion, a P/E ratio of 28.46, a P/E/G ratio of 2.39 and a beta of 0.51. LeMaitre Vascular has a 1 year low of $78.22 and a 1 year high of $118.01.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Citigroup reiterated a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Barrington Research lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Wednesday, August 5th. Weiss Ratings lowered LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 23rd. Wells Fargo & Company cut their target price on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating on the stock in a research report on Wednesday, August 5th. Finally, Wall Street Zen downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Three investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $110.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.

Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.

Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.